Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynectics Regulatory News (SNX)

Share Price Information for Synectics (SNX)

Share Price is delayed by 15 minutes
Get Live Data
200.00    0.00 (0.00%)
Bid:
195.00
Ask:
205.00
Spread: 10.00 (5.128%)
Market Cap: £34.01m
SNX Live PriceLast checked at - London Stock Exchange

Intraday Synectics Share Chart

Director/PDMR Shareholding

4 Oct 2022 07:00

RNS Number : 6145B
Synectics PLC
04 October 2022
Β 

Β 

Β 

RNS

Β 

4 October 2022

Β 

Β 

Synectics plc

("Synectics" or the "Company")

Β 

Director/PDMR dealings

Β 

Synectics plc (AIM: SNX), a leader in the design, integration and support of advanced security and surveillance systems, has been notified that on 3 October 2022, the Trustee of the Company's HMRC Approved Employee Share Acquisition Plan ("ESAP") purchased a total of 13,869 ordinary shares of 20 pence each in the Company ("Ordinary Shares") at a price of Β£1.10 per share in accordance with the ESAP's rules and on behalf of all ESAP participants, in respect of the six-month accumulation period ended on 30 September 2022.

Β 

Under the terms of the ESAP, participating members, including employees and a Director of the Company, contribute a fixed amount to the Trustee on a monthly basis. The Trustee acquires a number of shares at the end of the six-month accumulation period (the "Period") based upon the contributions made in the Period and determined by the lowest share price at either the beginning of the Period or on the date of purchase. In this instance, the share price used for the allocation of the number of shares for ESAP purposes was the price per share on the date of purchase which was Β£1.10.

Β 

As a result of this purchase, the Company has been notified that the following Executive Director and PDMR have acquired the following interests in Ordinary Shares:

Β 

Β 

Β 

Name

Β 

Β 

Position

Β 

Β 

Status

Number of Ordinary Shares purchased by the Trustee

Paul Webb

Chief Executive

Executive Director

819

Greg Alcorn

Divisional Director

PDMR

818

Β 

Following these purchases, the interests of Messrs Webb and Alcorn in the shares of the Company are as follows:

Β 

Name

Β 

Number of Ordinary Shares Held

Interest in Ordinary Shares in Share Schemes

Β 

Β 

Resultant Total Interest

Β 

Β 

% of Issued Share Capital

Paul Webb

57,115

513,176

570,291

3.20

Greg Alcorn

0

47,427

47,427

0.27

Β 

For further information, please contact:

Synectics plc

Tel: +44 (0) 114 280 2828

Claire Stewart, Company Secretary

email: legalandsecretarial@synecticsplc.com

www.synecticsplc.com

Shore Capital

Tel: +44 (0) 20 7408 4050

Tom Griffiths / David Coaten

Β 

Β 

Β Ends

Β 

About Synectics plc

Β 

Synectics (AIM: SNX) is a leader in the design, integration and support of advanced security and surveillance systems that enable clients around the world to protect their people, communities, and assets.

Β 

Founded over 30 years ago, Synectics has deep industry experience across gaming, energy, urban transport, public space and critical infrastructure projects. The Group's expert engineering teams work in partnership with customers to create integrated product and technology solutions, proven in the most complex and demanding operating environments.

Β 

Find out more at www.synecticsplc.com

Β 

Β 

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
DSHEASEDEDAAFFA
Date   Source Headline
9th Dec 20241:30 pmRNSHoldings in Company
9th Dec 20247:00 amRNSTrading Update
5th Dec 20247:00 amRNS$2.7 million Contract Awards
27th Nov 20247:00 amRNSHolding(s) in Company
25th Nov 20247:00 amRNSContract Awards
18th Nov 20247:00 amRNSAppointment of CEO and Award of Options
4th Nov 20247:00 amRNSContract Awards
3rd Oct 20247:00 amRNSHolding(s) in Company
3rd Oct 20247:00 amRNSHolding(s) in Company
2nd Oct 20247:00 amRNSPDMR dealings
16th Sep 20247:00 amRNSTrading Update
9th Sep 20247:00 amRNSUS$3.2 million contract award
4th Sep 20241:30 pmRNSPDMR Dealings
29th Aug 20247:00 amRNSPassing of Paul Webb, Chief Executive Officer
21st Aug 20247:00 amRNSNotifiable Interest in Shares
1st Aug 20241:45 pmRNSHoldings in Company
9th Jul 20244:40 pmRNSHoldings in Company
9th Jul 20247:00 amRNSHalf-year Report
21st Jun 20247:00 amRNSBoard Appointment
18th Jun 20247:00 amRNSUS$10 million contract win
13th Jun 202410:00 amRNSNotice of Investor Presentation
4th Jun 20247:00 amRNSTrading Update
15th May 20247:00 amRNSDirector/PDMR Dealings
24th Apr 202410:00 amRNSResult of AGM
24th Apr 20247:00 amRNSAGM Statement
17th Apr 20247:00 amRNSContract win with a major UK utility provider
9th Apr 20247:00 amRNSBoard Appointment and Grant of Options
3rd Apr 20247:00 amRNSDirector/PDMR Dealings
26th Mar 20247:00 amRNSDirectors / PDMRs' Interests in Shares
26th Mar 20247:00 amRNSDirector/PDMR Shareholding
19th Mar 20247:00 amRNSPosting of Annual Report & Accounts, Notice of AGM
27th Feb 20247:00 amRNSFinal Results
7th Feb 20247:00 amRNSNotice of Results and Investor Presentation
30th Jan 20247:00 amRNSContract Awards
19th Dec 20233:00 pmRNSHolding(s) in Company
11th Dec 20237:00 amRNSTrading Update
29th Nov 20237:00 amRNSContract Win
15th Nov 20237:00 amRNSInvestor Site Visit
23rd Oct 20237:00 amRNSDirectorate Changes
16th Oct 20237:00 amRNSLatest Release of Synectics’ Synergy Software
11th Oct 20237:00 amRNSDirector/PDMR Dealings
28th Sep 20237:00 amRNSAdditional Contract with West Midlands Police
11th Jul 20237:00 amRNSHalf-year Report
4th Jul 20237:00 amRNSContract Award
3rd Jul 20237:00 amRNSInvestor Presentation re interim results
19th Jun 20237:00 amRNSTrading Update and Notification of Results
11th May 20237:00 amRNSDirector dealings
2nd May 20237:00 amRNSNew Gaming Project in Asia
27th Apr 202311:51 amRNSResult of AGM
27th Apr 20237:00 amRNSAGM Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.